Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.07

-3.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John O'Neill who wrote (19417)	4/22/1998 4:01:00 PM
From: Henry Niman	Read Replies (1) of 32384

JO, I'm not sure where you got that impression. The press release clearly states that the SERM/Rexinoid combo would be for cancer: Lilly will receive: -- Rights to Targretin(TM), an oral therapy currently in early clinical development for Type II diabetes. Targretin is the first in a new class of oral diabetes therapies. -- Exclusive rights to two second generation oral diabetes compounds -- LGD1268 and LGD1324 -- in preclinical development that could offer further improvements over currently available products. -- Exclusive rights to Ligand's metabolic disease technology to develop more advanced diabetes, cardiovascular and related therapies. -- Additional rights to use Ligand technology to develop a compound in combination with a Selective Estrogen Receptor Modulator (SERM) in cancer." I don't think that it's much of a stretch to assume that the cancer will be breast cancer since it involves SERMs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next